Monoclonal TCR-redirected tumor cell killing

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• T cell immunity shows potential in eradicating cancer cells, but many patients experience T cell receptor (TCR)-mediated recognition failure.
• Existing immunotherapies face challenges in overcoming cancer's immune tolerance.
• Targeting tumor-associated antigens is crucial for effective cancer immunotherapy.

Purpose of the Study:

• To engineer and characterize novel reagents, termed immune-mobilizing monoclonal TCRs against cancer (ImmTACs).
• To evaluate the efficacy of ImmTACs in redirecting T cells against cancer cells, including those with low antigen expression.
• To assess the potential of ImmTACs as a new therapeutic strategy for cancer immunotherapy.

Main Methods:

• Engineering of ImmTACs by fusing tumor-associated epitope-specific monoclonal TCRs with CD3-specific single-chain antibody fragments (scFvs).
• Characterization of four distinct ImmTAC reagents with picomolar affinity.
• In vitro assessment of T cell redirection and cancer cell killing.
• In vivo studies to evaluate tumor growth suppression.

Main Results:

• Engineered ImmTACs effectively redirected T cells to kill cancer cells expressing extremely low surface epitope densities.
• Four distinct ImmTACs demonstrated potent tumor growth suppression in vivo.
• ImmTACs showed high affinity for tumor-associated epitopes, enabling precise T cell activation.

Conclusions:

• ImmTACs represent a novel class of reagents for cancer immunotherapy.
• These engineered molecules overcome immune tolerance, enhancing T cell-mediated cancer cell elimination.
• ImmTACs offer a promising new approach to treating cancer by improving T cell recognition and activation.